CSIMarket
 
Alimera Sciences Inc   (ALIM)
Other Ticker:  
 
 

Alimera Sciences Inc's Suppliers Performance

ALIM's Supply Chain

 
ALIM Costs vs Sales of Suppliers Growth Alimera Sciences Inc recorded an increase in cost of sales by 70.64 % year on year, sequentially cost of sales grew by 31.47 % in Q4.

More on ALIM Suppliers




Alimera Sciences Inc recorded increase in cost of sales by 70.64 % year on year, sequentially cost of sales grew by 31.47 % in Q4.

More on ALIM Suppliers



  News about Alimera Sciences Inc Contracts

Advancements in Radiation Retinopathy Treatment: ILUVIEN and Faricimab Injections Show Promise

Radiation retinopathy is a severe side effect of radiation therapy, causing visual acuity loss and potentially leading to blindness. The groundbreaking research study conducted by the DRCR Retina Network, in partnership with Alimera Sciences, explores the efficacy of ILUVIEN and faricimab (6.0 mg) injections compared to observation in preventing visual acuity loss due to radiation retinopathy. This trial, known as Protocol AL, offers new hope for patients and represents a significant milestone in the field of ophthalmology.The Facts:In the Radiation Retinopathy Trial, the first patient has been successfully randomized, marking the commencement of this pivotal research endeavor. Protocol AL aims to investigat...

Alimera's Breakthrough Synchronicity Study with YUTIQ Surges Past Recruitment Goal: A Game-Changer in Ophthalmology

Alimera Sciences, a renowned pharmaceutical company specializing in ophthalmic solutions, recently announced the completion of patient recruitment for their groundbreaking Synchronicity Study. This significant milestone marks a major breakthrough in the field of ophthalmology, as the study has successfully surpassed its initial goal of enrolling 100 patients.The Synchronicity Study, in partnership with Alimera's innovative YUTIQ, aims to evaluate the safety and efficacy of this remarkable sustained-release intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye. Alimera has consistently demonstrated their commitment to revolutionizing the treatment land...




Alimera Sciences Inc's Comment on Supply Chain









ALIM's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Alimera Sciences Inc 98.55 79.92 -20.13 -
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com